Akoya Biosciences (AKYA) Projected to Post Earnings on Monday

Akoya Biosciences (NASDAQ:AKYA) is anticipated to issue its quarterly earnings data before the market opens on Monday, March 3rd. Analysts expect the company to announce earnings of ($0.15) per share and revenue of $21.34 million for the quarter.

Akoya Biosciences Trading Down 0.2 %

Shares of Akoya Biosciences stock opened at $2.06 on Monday. The company has a current ratio of 2.75, a quick ratio of 1.85 and a debt-to-equity ratio of 5.62. Akoya Biosciences has a 12-month low of $1.88 and a 12-month high of $6.31. The stock has a market cap of $101.87 million, a price-to-earnings ratio of -1.74 and a beta of 1.23. The company has a fifty day simple moving average of $2.58 and a 200-day simple moving average of $2.61.

Wall Street Analyst Weigh In

AKYA has been the subject of several research analyst reports. Craig Hallum downgraded Akoya Biosciences from a “buy” rating to a “hold” rating and decreased their price objective for the company from $7.00 to $5.00 in a report on Friday, November 15th. Canaccord Genuity Group lowered Akoya Biosciences from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $3.00 price objective (down from $4.00) on shares of Akoya Biosciences in a research report on Tuesday, November 19th. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $5.43.

Institutional Trading of Akoya Biosciences

An institutional investor recently raised its position in Akoya Biosciences stock. Bank of America Corp DE grew its stake in shares of Akoya Biosciences, Inc. (NASDAQ:AKYA) by 39.6% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 29,092 shares of the company’s stock after purchasing an additional 8,258 shares during the period. Bank of America Corp DE owned approximately 0.06% of Akoya Biosciences worth $67,000 at the end of the most recent reporting period. 79.42% of the stock is currently owned by institutional investors.

Akoya Biosciences Company Profile

Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.